

Human TERT siRNA

Catalogue No.:abx905526

siRNA to inhibit TERT expression using RNA interference.

This product is provided as three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot.

| Target: | TERT | | | | |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------|----------------------------|-----------------------------------|
| Reactivity: | Human | | | | |
| Tested Applications: | RNAi | | | | |
| Host: | Synthetic | | C | 6 | |
| Recommended | Optimal dilutions/concentrations should be determined by the end user. | | | | |
| | | | | | |
| dilutions: | Plate (wells) | Final Medium Volume (ml) | Final siRNA Concentration (nM) | 20 µM siRNA Volume (µl) | Lipofectamine 2000 Volume (µl) |
| | (wens) | volume (m) | 100 | 0.5 | 0.25 |
| | 96 | 0.1 | 50 | 0.25 | 0.25 |
| | 00 | 0.1 | 10 | 0.05 | 0.25 |
| | | | 100 | 2.5 | 1 |
| | 24 | 0.5 | 50 | 1.25 | 1 |
| | | | 10 | 0.25 | 1 |
| | | | 100 | 5 | 2 |
| | 12 | 1 | 50 | 2.5 | 2 |
| | | | 10 | 0.5 | 2 |
| | | | 100 | 10 | 5 |
| | 6 | 2 | 50 | 5 | 5 |
| | | | 10 | 1 | 5 |
| Form: | Lyophilized | d | | | |
| Purity: | > 97% | | | | |
| Quality Control: | Oligopuelo | otido overthopia ia | monitored base by base t | through tritul analysis | to opouro oppropriato |
| Quality Control. | Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The | | | | |
| | | | | | |
| | annealed I | RNA duplex is furt | her analyzed by mass spe | ectrometry to verify th | e exact composition of |
| | the dunley | Each lot is comp | ared to the previous lot by | w mass spectrometry | to ensure maximum lot- |
| | • | • | | y made opeon officially | |
| | to-lot cons | istency. | | | |
| Storage: | Shipped at 4 °C. Store at -20 °C for up to one year. | | | | |
| UniProt Primary AC: | O14746 (<u>UniProt</u> , <u>ExPASy</u>) | | | | |
| Gene Symbol: | TERT | | | | |

Datasheet Version: 3.0.0

Revision date: 13 Mar 2025



| GenelD: | <u>7015</u> |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NCBI Accession: | NM_001193376.1 |
| KEGG: | hsa:7015 |
| Specificity: | TERT siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression. |
| Note: | This product is for research use only. |
| Directions for use: | 1. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. 2. Resuspend the siRNA oligos to an appropriate concentration with DEPC water (e.g. resuspend one vial of 5 nmol siRNA oligo in 250 µl of DEPC water for a final concentration of 20 µM). 3. Transfect with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis. |